SMPD1 rs28942083: What Your Genotype Means

What each genotype means

Understanding the SMPD1 Gene

The SMPD1 gene provides instructions for producing an enzyme called acid sphingomyelinase. This enzyme is located within lysosomes, which are the recycling centers of the cell. Its primary function is to break down a fatty substance called sphingomyelin into ceramide. When the SMPD1 gene contains pathogenic variants, the body may not produce enough functional acid sphingomyelinase. This leads to the accumulation of sphingomyelin within cells, which can impair their function and lead to the clinical manifestations of acid sphingomyelinase deficiency (ASMD), historically known as Niemann-Pick disease types A and B. These conditions are inherited in an autosomal recessive pattern, meaning an individual typically needs to inherit two copies of a pathogenic variant—one from each parent—to manifest the disease.

What is the rs28942083 Variant?

The rs28942083 variant, also identified as p.Arg498Leu, is a missense mutation where a single nucleotide change results in the substitution of the amino acid arginine with leucine at position 498 of the SMPD1 protein. This specific alteration is classified as pathogenic in clinical databases. Because it affects the structure and function of the acid sphingomyelinase enzyme, it is a focus of genetic screening, particularly for individuals interested in their carrier status. Being a carrier means an individual has one copy of the variant and one functional copy of the gene, typically showing no symptoms of the disease themselves. However, carriers have a chance of passing the variant to their children. If both parents are carriers, there is a 25% chance for each pregnancy that the child will inherit two copies of the variant and potentially develop ASMD.

Evidence and Clinical Significance

The evidence linking rs28942083 to Niemann-Pick disease is well-established in clinical genetics. It is documented in databases like ClinVar as a pathogenic variant. Research indicates that this variant, along with others in the SMPD1 gene, is responsible for the reduced enzyme activity observed in patients with ASMD. While the association with the disease is strong, the clinical expression can vary, ranging from severe, early-onset forms (Type A) to milder, later-onset forms (Type B). It is important to note that genetic testing for this variant is often performed as part of a broader carrier screening panel. Because the evidence is specific to the pathogenicity of the variant, it is used primarily for reproductive counseling and family planning rather than for predicting individual health outcomes in the absence of a full clinical evaluation.

Population Frequency and Interpretation

The frequency of the rs28942083 variant varies significantly across different ancestral groups. It is most notably observed in the Ashkenazi Jewish population, where it is tracked as a known carrier marker. Globally, the variant is considered rare in the general population. Because it is an autosomal recessive condition, the presence of this variant in a single copy (heterozygosity) does not cause the disease. However, in populations where the variant is more common, the likelihood of two carriers meeting and having children is higher, which is why carrier screening is often recommended for those with specific ancestral backgrounds. If you have received a result indicating you are a carrier for this variant, it is recommended to consult with a genetic counselor or a medical professional to discuss the implications for your family planning and to understand the context of your specific genetic report.

Frequently asked questions

Sources & further reading

Related variants in SMPD1